BRAF and cancer: In multiple studies, combination therapy with dabrafenib and trametinib has shown improved survival rates and progression-free survival for patients afflicted with BRAF-V600-mutant metastatic malignant melanoma [6, 7, 11] as well as for other patients with non-melanoma cancers [22, 23].